XML 34 R25.htm IDEA: XBRL DOCUMENT
v3.22.2

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2022
Concentration Risk And Geographic Information [Abstract] |
Schedule of Net Product Revenues by Product | The following table disaggregates total Net Product Revenues by product.
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Net product revenues by product: |  |  |  |  |  |  |
Vimizim | $ | 173,206 |  |  | $ | 171,655 |  |  | $ | 356,265 |  |  | $ | 329,953 |
Naglazyme | 115,783 |  |  | 118,813 |  |  | 243,814 |  |  | 226,149 |
Palynziq | 61,643 |  |  | 58,935 |  |  | 116,528 |  |  | 112,973 |
Kuvan | 57,602 |  |  | 78,807 |  |  | 116,939 |  |  | 149,570 |
Brineura | 37,725 |  |  | 30,332 |  |  | 73,898 |  |  | 57,657 |
Voxzogo | 34,374 |  |  | — |  |  | 54,032 |  |  | — |
Total net product revenues marketed by the Company | 480,333 |  |  | 458,542 |  |  | 961,476 |  |  | 876,302 |
Aldurazyme net product revenues marketed by Sanofi | 37,327 |  |  | 28,128 |  |  | 61,709 |  |  | 78,137 |
Total net product revenues | 517,660 |  |  | 486,670 |  |  | 1,023,185 |  |  | 954,439 |
Royalty and other revenues | 16,138 |  |  | 15,023 |  |  | 29,972 |  |  | 33,284 |
Total revenues | $ | 533,798 |  |  | $ | 501,693 |  |  | $ | 1,053,157 |  |  | $ | 987,723 |
Schedule of Total Net Product Revenues Based on Patient Location | The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for Company's commercial products sold directly by the Company, except for Aldurazyme, which is sold exclusively by Sanofi worldwide.
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
United States | $ | 169,838 |  |  | $ | 169,411 |  |  | $ | 320,653 |  |  | $ | 324,474 |
Europe | 161,230 |  |  | 166,704 |  |  | 318,062 |  |  | 315,576 |
Latin America | 89,911 |  |  | 42,248 |  |  | 152,455 |  |  | 101,953 |
Rest of world | 59,354 |  |  | 80,179 |  |  | 170,306 |  |  | 134,299 |
Total net product revenues marketed by the Company | $ | 480,333 |  |  | $ | 458,542 |  |  | $ | 961,476 |  |  | $ | 876,302 |
Aldurazyme net product revenues marketed by Sanofi | 37,327 |  |  | 28,128 |  |  | 61,709 |  |  | 78,137 |
Total net product revenues | $ | 517,660 |  |  | $ | 486,670 |  |  | $ | 1,023,185 |  |  | $ | 954,439 |
Schedule of Net Product Revenue Concentrations Attributed to Largest Customers | The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2022 |  | 2021 |  | 2022 |  | 2021
Customer A | 16 | % |  | 16 | % |  | 16 | % |  | 16 | %
Customer B | 12 | % |  | 13 | % |  | 12 | % |  | 13 | %
Customer C | 5 | % |  | 12 | % |  | 5 | % |  | 10 | %
Total | 33 | % |  | 41 | % |  | 33 | % |  | 39 | %

X
- Definition Concentration risk and geographic information. + References No definition available. + Details
Name: | bmrn_ConcentrationRiskAndGeographicInformationAbstract
Namespace Prefix: | bmrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration